12:49 PM EDT, 10/16/2025 (MT Newswires) -- Vera Therapeutics ( VERA ) offers a compelling entry point ahead of its anticipated mid-2026 commercial launch of atacicept, which could transform the treatment of immunoglobulin A nephropathy, BofA Securities said in a note Thursday.

BofA said atacicept's launch could exceed consensus estimates by 15% to 20% and ease competitive risk concerns as it launches into a multi billion dollar market.

Atacicept, designed to inhibit B-cell overactivity that drives autoimmune disorders, is being developed as a once weekly self-administered at-home injection.

BofA forecasts peak sales of about $3 billion by 2037, supported by potential label expansions and life-cycle management efforts that could extend its use to other rare kidney diseases.

The firm said Vera's pipeline of biologics targeting B-cell modulation, including MAU868 and VT-109, provide additional long-term upside in autoimmune disorders beyond immunoglobulin A nephropathy.

BofA initiated coverage of Vera Therapeutics ( VERA ) with a buy rating and a $48 price target.

Price: 30.68, Change: -0.32, Percent Change: -1.03